Drug intelligence / Profile preview

quetiapine or olanzapine or risperidone or aripiprazole

Development stage
Approved
Lead developer
AstraZeneca
Modality
Small Molecules
Administration
Oral, Intramuscular, Subcutaneous
01

Overview

This entry refers to a group of four atypical (second-generation) antipsychotic drugs: quetiapine, olanzapine, risperidone, and aripiprazole. These medications are primarily used for the treatment of schizophrenia, bipolar disorder, and other psychiatric conditions. They act mainly by modulating neurotransmitter activity in the brain—primarily dopamine D2 receptor antagonism (except for aripiprazole, which is a partial agonist at D2), as well as effects on serotonin receptors (notably 5-HT2A antagonism). Each drug has a unique receptor binding profile that influences its efficacy and side effect spectrum. Quetiapine is known for its sedative properties; olanzapine is associated with significant metabolic side effects; risperidone can cause hyperprolactinemia; and aripiprazole tends to have fewer metabolic adverse effects due to its partial agonist action at dopamine receptors[1][3][5].

Brand names
SeroquelZyprexaRisperdalAbilify
Other names
quetiapine fumarateolanzapine pamoaterisperidone tartratearipiprazole lauroxil
02

Targets

HTR2A (Serotonin receptor 5-HT2A)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2C (5-hydroxytryptamine 2C receptor)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)

Beyond the preview

Go deeper on quetiapine or olanzapine or risperidone or aripiprazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on quetiapine or olanzapine or risperidone or aripiprazole.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call